Stockpolly
Search
MLTX · NASDAQ · Biotechnology

MoonLake Immunotherapeutics (MLTX)

Develops sonelokimab for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis.

$15.03
Pre-market−0.04 (−0.28%)
At close$15.07(−0.40%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000010110
Gross profit0000000−10−1−10
131520314350476071646962
Research & development8813243640364961575450
57777911111191611
General & administrative57770911111191611
Other expenses000000000−200
Operating income−13−15−20−31−43−50−47−61−71−65−70−62
176673751210
Interest expense000000023223
Other non-operating income0−7−6−6−7−3−7−7−4−4−3−3
Income before tax−12−8−14−25−36−46−40−56−71−63−69−62
Income tax expense000000000010
Net income from continuing operations−12−8−14−25−36−46−41−56−71−63−70−62
Net income−9−7−14−24−35−46−40−55−70−62−70−62
EPS, basic−$0.18−$0.12−$0.22−$0.39−$0.56−$0.72−$0.63−$0.87−$1.10−$0.93−$0.98−$0.84
EPS, diluted−$0.18−$0.12−$0.22−$0.39−$0.56−$0.72−$0.63−$0.87−$1.10−$0.93−$0.98−$0.84
Weighted average shares, basic546063636363636363647174
Weighted average shares, diluted546063636363636363647174
EBITDA−13−8−14−24−36−45−40−53−67−60−66−58
Depreciation & amortization000001011111
EBIT−13−8−14−25−36−46−40−54−67−61−67−59